Working in partnership with 51福利社 University NHS Foundation Trust and Roche, the team developed the project - REVISE-HCC.

The REVISE-HCC project, funded by SBRI Healthcare /NHS England, was established to explore the use of an innovative test for liver cancer, which will help patients access earlier care and potentially save lives.

This project focused on implementing an improved strategy for liver cancer surveillance in patients who are at high risk by using the GAAD algorithm developed by Roche.

GAAD is an accurate test that combines blood tests with gender and age to indicate the presence of HCC (Hepatocellular carcinoma), which is the most common cause of cancer affecting the liver and a leading  cause for cancer-related deaths worldwide. The test is used alongside routine HCC surveillance tests to see how it can benefit patients.

With the  combined purpose to improve the detection rate for this deadly cancer at curable stages and improve the quality of life for these patients, we鈥檙e thrilled to receive this recognition.

Healthcare is rapidly shifting, towards more personalised care that鈥檚 more in tune with patients, embracing digital technologies that enable new possibilities. We鈥檙e excited to be at the forefront of this new class of diagnostic algorithms that our teams are helping to shape.

Programme Manager  Oliver Street said:  鈥�51福利社 has some of the highest rates of liver disease and liver cancer in the UK and is a significant healthcare and societal burden. Far too many people are diagnosed too late when curative treatment is not possible.

鈥淲e were thrilled to be recognised at this year鈥檚 HSJ Partnership Awards for our partnership with Roche and 51福利社 University NHS Foundation Trust that implemented this innovative technology at MFT and allows for more patients with liver cancer to be detected an early stage when their cancer is potentially curable.鈥�